Trial Profile
Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 01 Mar 2019 Primary endpoint (Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at the End of the Treatment Period 1 (TP1)) has not been met, according to the results published in the Pediatric Allergy and Immunology
- 01 Mar 2019 Results published in the Pediatric Allergy and Immunology
- 28 Mar 2017 Status changed from active, no longer recruiting to completed.